Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Baseline characteristics of 80 patients receiving the SSTS for postoperative pain-management

From: Sublingual sufentanil after orthopaedic and abdominal surgery: long-term outcome and safety

Age (in years)

 Median

67

 Maximum

87

 Minimum

32

Gender (m/f)

 Female

45 (56.3%)

 Male

35 (43.8%)

BMI (kg/m2)

 Mean (± SDT)

29.1 (± 5.9)

Surgery

 Knee joint arthrosis

n = 71 (88.8%)

 Abdominal surgery

n = 9 (11.3%)

ASA (American Society of Anesthesiologists)

 ASA I

n = 7 (8.8%)

 ASA II

n = 58 (72.5%)

 ASA III

n = 13 (16.3%)

NYHA (New York Heart Association)

 NYHA I

n = 44 (55%)

 NYHA I

n = 32 (40%)

 NYHA III

n = 1 (1.3%)

Chronic pain-medication

 WHO I

n = 20 (25%)

 WHO II/III

n = 11 (13.8%)

Peri-operative hypnotics

 TIVA with propofol

n = 15 (18.8%)

 Balanced anaesthesia

n = 32 (40%)

 Other (including spinal anaesthesia)

n = 33 (41.3%)

Intraoperative PONV-prophylaxis

 Dexamethasone

n = 39 (48.8%)

 Ondansetrone

n = 33 (41.3%)

Intraoperative crystalloids (in ml)

 Mean (± SDT)

1667 (± 706)

Patients with intraoperative catecholamines

n = 15 (18.8%)

Patients with PONV

n = 6 (7.5%)